Ownership Summary
A total of 2 institutions have reported a stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) as of December 2025, according to recent 13F filings with the SEC.
- Institutional ownership in Indaptus Therapeutics edged up to 2.9% in December 2025, compared to 2.0% in September 2025.
- On a quarter-over-quarter basis, institutional holdings shifted by 5491.33%, with a year-over-year a decrease of 90.00% in the count of filers.
- Among the 2 institutional holders of Indaptus Therapeutics, 1 added to their stakes while 0 trimmed their positions and 1 held steady.
- This class of investors increased its holdings in Indaptus Therapeutics to 29.02K shares for the 13F-cycle ending December 2025, up by 28.50K shares quarter on quarter, and down 609.39K shares year over year.
- UBS Group AG's holding of 29.00K shares as of December 31, 2025 makes it the primary institutional investor in Indaptus Therapeutics, owning 2.90% of the stock.
- Among the most significant buyers of Indaptus Therapeutics during December 2025 were UBS Group AG (28.50K).
- The top 2 institutional holders of Indaptus Therapeutics for the quarter ending December 2025 included UBS Group AG (29.00K), SBI Securities Co., Ltd. (17).